JPMAM, UBS GWM launch genetic therapies fund

JP Morgan Asset Management has launched the JPMAM Genetic Therapies fund in partnership with UBS Global Wealth Management, to target what it sees as "disruptive technology for the pharmaceutical and biotechnology industry". An active equity strategy, the fund uses research done by UBS Global Wealth Management's Chief Investment Office within its Longer Term Investments framework, and is being distributed by UBS initially. Co-managers are Yazann Romahi, Berkan Sesen and Aijaz Hussein, who sit within JPMAM's Quantitative Beta Strategies team, which specialises on quantitative portfolio ...